Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Curr Opin Endocrinol Diabetes Obes. 2012 Jun;19(3):220–227. doi: 10.1097/MED.0b013e3283534b11

Figure 3.

Figure 3

The distribution of currently known functional polymorphisms, and activating and inactivating mutations across the human FSHR gene. The FSHR exon boundaries are marked with short bars striking through the protein sequence. Greycircles depict the activating, greysquares inactivating mutations, and the asterisks the polymorphisms. The two polymorphisms Thr307Ala and Asn680Ser with currently known pharmacogenetic significance and exhibiting linkage disequilibrium in most populations are marked in bold. An additionalpolymorphism that has been indicated to have pharmacogenetic potential is FSHR–29G/A located in 5′-untranslated region and thus, not presented in this figure.